4 results on '"Huang, Kezhi"'
Search Results
2. A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.
- Author
-
Yang M, Pan Z, Huang K, Büsche G, Liu H, Göhring G, Rumpel R, Dittrich-Breiholz O, Talbot S, Scherr M, Chaturvedi A, Eder M, Skokowa J, Zhou J, Welte K, von Neuhoff N, Liu L, Ganser A, and Li Z
- Subjects
- Animals, Gene Duplication, Gene Knock-In Techniques, Mice, Mice, Inbred C57BL, Mutation, Gene Expression Regulation, Leukemic, Haploinsufficiency, Leukemia, Myeloid, Acute genetics, Tumor Suppressor Protein p53 genetics, fms-Like Tyrosine Kinase 3 genetics
- Abstract
With an incidence of ~50%, the absence or reduced protein level of p53 is much more common than TP53 mutations in acute myeloid leukemia (AML). AML with FLT3-ITD (internal tandem duplication) mutations has an unfavorable prognosis and is highly associated with wt-p53 dysfunction. While TP53 mutation in the presence of FLT3-ITD does not induce AML in mice, it is not clear whether p53 haploinsufficiency or loss cooperates with FLT3-ITD in the induction of AML. Here, we generated FLT3-ITD knock-in; p53 knockout (heterozygous and homozygous) double-transgenic mice and found that both alterations strongly cooperated in the induction of cytogenetically normal AML without increasing the self-renewal potential. At the molecular level, we found the strong upregulation of Htra3 and the downregulation of Lin28a, leading to enhanced proliferation and the inhibition of apoptosis and differentiation. The co-occurrence of Htra3 overexpression and Lin28a knockdown, in the presence of FLT3-ITD, induced AML with similar morphology as leukemic cells from double-transgenic mice. These leukemic cells were highly sensitive to the proteasome inhibitor carfilzomib. Carfilzomib strongly enhanced the activity of targeting AXL (upstream of FLT3) against murine and human leukemic cells. Our results unravel a unique role of p53 haploinsufficiency or loss in the development of FLT3-ITD + AML., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
3. Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library.
- Author
-
Tian T, Zhang S, Luo B, Yin F, Lu W, Li Y, Huang K, Liu Q, Huang P, Garcia-Manero G, Wen S, and Hu Y
- Subjects
- Animals, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Benzimidazoles chemistry, Benzimidazoles pharmacokinetics, Cell Line, Cell Line, Tumor, High-Throughput Screening Assays, Humans, Leukemia drug therapy, Male, Mice, Mice, Inbred BALB C, Protein Kinase Inhibitors pharmacology, Rats, Rats, Sprague-Dawley, Small Molecule Libraries, Solubility, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Benzimidazoles pharmacology, fms-Like Tyrosine Kinase 3 antagonists & inhibitors
- Abstract
Internal tandem duplication in the FLT3 receptor tyrosine kinase (FLT3/ITD mutation) occurs in approximately 25% of acute myeloid leukemia (AML) patients. To specifically target this driver mutation in AML, we assessed and compared the cell-based cytotoxicity of a diversity library (10,000 compounds) against the normal cell line BaF3 and the isogenic leukemic cell line BaF3/ITD. A benzoimidazole scaffold-based compound (HP1142) was identified as the most selective compound against a series of murine and human leukemia cells with FLT3/ITD. Novel benzoimidazole compounds were further designed to improve the aqueous solubility of HP1142. The most potent compound, HP1328, demonstrated desirable pharmaceutical and pharmacokinetic properties. Treatment with HP1328 significantly reduced the leukemia burden and prolonged the survival of mice with FLT3/ITD leukemia. Our findings establish the specific activity of the benzoimidazole compound against FLT3/ITD leukemia and warrant further investigation in this subset of leukemia patients with poor prognosis.
- Published
- 2022
- Full Text
- View/download PDF
4. Leukemogenic potency of the novel FLT3-N676K mutant.
- Author
-
Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, and Li Z
- Subjects
- Amino Acid Substitution, Animals, Antineoplastic Agents therapeutic use, Benzimidazoles therapeutic use, Benzothiazoles therapeutic use, Bone Marrow Transplantation, Cell Transformation, Neoplastic genetics, Gene Expression Regulation, Leukemic, Genetic Predisposition to Disease, Genetic Vectors, Humans, Leukemia, Experimental drug therapy, Leukemia, Experimental enzymology, Mice, Mice, Inbred C3H, Mice, Inbred C57BL, Neoplasm Transplantation, Neoplastic Stem Cells transplantation, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion physiology, Phenylurea Compounds therapeutic use, Piperidines therapeutic use, Protein Kinase Inhibitors therapeutic use, Protein Processing, Post-Translational genetics, Radiation Chimera, Retroviridae, Tandem Repeat Sequences, Transgenes, Tumor Stem Cell Assay, fms-Like Tyrosine Kinase 3 antagonists & inhibitors, fms-Like Tyrosine Kinase 3 physiology, Leukemia, Experimental genetics, Mutation, Missense, Point Mutation, fms-Like Tyrosine Kinase 3 genetics
- Abstract
The novel FMS-like tyrosine kinase 3 (FLT3)-N676K point mutation within the FLT3 kinase domain-1 was recently identified in 6 % of de novo acute myeloid leukemia (AML) patients with inv(16). Because FLT3-N676K was encountered almost exclusively in inv(16) AML, we investigated the transforming potential of FLT3-N676K, the cooperation between FLT3-N676K and core binding factor ß-smooth muscle myosin heavy chain (CBFß-SMMHC) (encoded by the inv(16) chimeric gene CBFB-MYH11) in inducing acute leukemia, and tested the sensitivity of FLT3-N676K-positive leukemic cells to FLT3 inhibitors. Retroviral expression of FLT3-N676K in myeloid 32D cells induced AML in syngeneic C3H/HeJ mice (n = 11/13, median latency 58 days), with a transforming activity similar to FLT3-internal tandem duplication (ITD) (n = 8/8), FLT3-TKD D835Y (n = 8/9), and FLT3-ITD-N676K (n = 9/9) mutations. Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD. Moreover, co-expression of FLT3-N676K/CBFß-SMMHC did not promote acute leukemia in three independent experiments (n = 16). In comparison with FLT3-ITD, FLT3-N676K induced much higher activation of FLT3 and tended to trigger stronger phosphorylation of MAPK and AKT. Importantly, leukemic cells carrying the FLT3-N676K mutant in the absence of an ITD mutation were highly sensitive to FLT3 inhibitors AC220 and crenolanib, and crenolanib even retained activity against the AC220-resistant FLT3-ITD-N676K mutant. Taken together, the FLT3-N676K mutant is potent to transform murine hematopoietic stem/progenitor cells in vivo. This is the first report of acute leukemia induced by an activating FLT3 mutation in C57BL/6J mice. Moreover, further experiments investigating molecular mechanisms for leukemogenesis induced by FLT3-N676K mutation and clinical evaluation of FLT3 inhibitors in FLT3-N676K-positive AML seem warranted.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.